Pingtan Marine Ent (MM) (CGEIW) News

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage...

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update

-- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On...

Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean...

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of...

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage...

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage...

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage...

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed...

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage...